Ignacio G.
- Country
- Spain
- Department
- Medical Oncology
Research Overview
- Subcutaneous Dermatophagoides/Lepidoglyphus immunotherapy for moderate-to-severe allergic rhinitis/rhinoconjunctivitis with mild-to-moderate asthma: randomized placebo-controlled trial
- Phase II Evaluation of Atezolizumab and Tiragolumab with Chemoradiotherapy in Localized Squamous Cell Carcinoma of the Anal Canal
- Efficacy and safety of MG01 and T517 drug combination in patients with allergic rhinitis or rhinoconjunctivitis, with or without mild‑moderate asthma
Data & Insights
Has run more than one trial at 10 of 59 partner sites.
Specializations
Gastrointestinal Oncology
The investigator specializes in treating advanced gastrointestinal cancers, with particular expertise in pancreatic ductal adenocarcinoma and anal canal carcinoma.
- Metastatic Pancreatic Cancer Management
- Anal Canal Squamous Cell Carcinoma
- Advanced GI Cancer Therapeutics
Their research focuses on integrating novel therapeutic approaches with established treatment protocols for gastrointestinal malignancies.
Immunotherapy Research
The investigator explores innovative immunotherapeutic approaches in cancer treatment, particularly focusing on combination immunotherapy strategies.
- Novel Immunotherapy Combinations
- Immune Checkpoint Inhibition
- Chemoimmunotherapy Integration
Their work includes evaluating the effectiveness of dual immunotherapy agents in combination with standard treatment modalities.
Combined Modality Treatment
The investigator develops multimodal treatment strategies, incorporating chemoradiotherapy with novel therapeutic agents.
- Chemoradiation Protocols
- Combined Treatment Approaches
- Novel Drug Combinations
Their research examines the integration of targeted therapies with conventional treatment methods to enhance therapeutic outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.